| 27.765 -0.735 (-2.58%) | 10-09 15:39 | |||||||||||||
|
|
| Short term |   |
|||
| Mid term |  |
|||
| Targets | 6-month : | 35.74 | 1-year : | 41.75 |
| Resists | First : | 30.6 | Second : | 35.74 |
| Pivot price | 27.96  |
|||
| Supports | First : | 24.42 | Second : | 20.6 |
| MAs | MA(5) : | 28.7 |
MA(20) : | 26.66 |
| MA(100) : | 20.28 |
MA(250) : | 0 | |
| MACD | MACD : | 1.4 |
Signal : | 1.6 |
| %K %D | K(14,3) : | 69.9 |
D(3) : | 77.8 |
| RSI | RSI(14): 53.5 |
|||
| 52-week | High : | 30.6 | Low : | 7.25 |
Price has closed below its short-term moving average. Short-term moving average is currently above mid-term; and above long-term moving average. From the relationship between price and moving averages: This stock is NEUTRAL in short-term; and BULLISH in mid-long term.[ SION ] has closed above bottom band by 38.2%. Bollinger Bands are 9.2% wider than normal. The current width of the bands does not suggest anything about the future direction or movement of prices.
| If tomorrow: | Open lower | Open higher |
| High: | 28.78 - 28.95 | 28.95 - 29.08 |
| Low: | 27.14 - 27.36 | 27.36 - 27.53 |
| Close: | 28.2 - 28.54 | 28.54 - 28.79 |
Sionna Therapeutics, Inc. is a biopharmaceutical company. The Company provides treatment paradigm for cystic fibrosis patients by developing medicines that normalize the function of the cystic fibrosis transmembrane conductance regulator.
Mon, 06 Oct 2025
Only Mass. biotech to go public this year grows headcount 71% - The Business Journals
Fri, 03 Oct 2025
Sionna Therapeutics (SION): Exploring Valuation After Recent 15% Share Price Climb - Sahm
Wed, 01 Oct 2025
Sionna Therapeutics to Present Data at the 2025 North American Cystic Fibrosis Conference - The Manila Times
Wed, 24 Sep 2025
Sionna Stock Hits New High - From $13 To $27 In Less Than 5 Months; Did You Miss The Boat? - RTTNews
Mon, 15 Sep 2025
All You Need to Know About Sionna Therapeutics, Inc. (SION) Rating Upgrade to Buy - Yahoo Finance
Tue, 09 Sep 2025
Wall Street Analysts See a 66.51% Upside in Sionna Therapeutics, Inc. (SION): Can the Stock Really Move This High? - Yahoo Finance
| Price to Book Value: P/BV, a ratio used to compare book value to its current market price, to gauge whether a stock is valued properly. |
Neutral |
| Price to Earnings: PE, the ratio for valuing a company that measures its current share price relative to its earnings per share (EPS). |
Underperform |
| Discounted cash flow: DCF, a valuation method used to estimate the value of an investment based on its expected future cash flows. |
Neutral |
| Return on Assets: ROA, indicates how profitable a company is in relation to its total assets, how efficiently uses assets to generate a profit. |
Underperform |
| Return on Equity: ROE, a measure of financial performance calculated by dividing net income by equity. a gauge of profitability and efficiency. |
Underperform |
| Debt to Equity: evaluate financial leverage, reflects the ability of equity to cover outstanding debts in the event of a business downturn. |
Underperform |
|
Exchange:
NASDAQ
|
|
|
Sector:
Healthcare
|
|
|
Industry:
Biotechnology
|
|
| Shares Out | 44 (M) |
| Shares Float | 11 (M) |
| Held by Insiders | 7 (%) |
| Held by Institutions | 97.9 (%) |
| Shares Short | 3,770 (K) |
| Shares Short P.Month | 3,600 (K) |
| EPS | -1.73 |
| EPS Est Next Qtrly | 0 |
| EPS Est This Year | 0 |
| EPS Est Next Year | 0 |
| Book Value (p.s.) | 7.61 |
| Profit Margin | 0 % |
| Operating Margin | 0 % |
| Return on Assets (ttm) | 0 % |
| Return on Equity (ttm) | 0 % |
| Qtrly Rev. Growth | 0 % |
| Gross Profit (p.s.) | 0 |
| Sales Per Share | 0 |
| EBITDA (p.s.) | -1.98 |
| Qtrly Earnings Growth | 0 % |
| Operating Cash Flow | -64 (M) |
| Levered Free Cash Flow | 0 (M) |
| PE Ratio | -15.79 |
| PEG Ratio | 0 |
| Price to Book value | 3.56 |
| Price to Sales | 0 |
| Price to Cash Flow | -18.76 |
| Dividend | 0 |
| Forward Dividend | 0 |
| Dividend Yield | 0% |
| Dividend Pay Date | Invalid DateTime. |
| Ex-Dividend Date | Invalid DateTime. |
|
|
|
|
|
|
|
|
|